SUBCLINICAL KIDNEY INJURY IS CAUSED BY A MODERATE SINGLE INFLAMMATORY EVENT.
Journal
Shock (Augusta, Ga.)
ISSN: 1540-0514
Titre abrégé: Shock
Pays: United States
ID NLM: 9421564
Informations de publication
Date de publication:
01 07 2022
01 07 2022
Historique:
pubmed:
27
5
2022
medline:
24
8
2022
entrez:
26
5
2022
Statut:
ppublish
Résumé
Background: Current means of diagnosis of acute kidney injury (AKI) based on serum creatinine have poor sensitivity and may miss possible therapeutic windows in subclinical kidney injury, especially in septic AKI. Kidney injury molecule-1 (KIM-1) may be a valuable biomarker to improve diagnostic algorithms for AKI. The understanding of septic AKI is still insufficient, and knowledge about KIM-1 kinetics in inflammation is scarce. The aim of this study was to investigate the possible effect of lipopolysaccharide (LPS) on KIM-1 as a marker of structural kidney injury in healthy volunteers. Methods: A single-blinded, placebo-controlled cross-over study using the human endotoxin model (LPS administration) was performed in 10 healthy men. Kidney injury molecule-1 and serum creatinine were measured repetitively for 48 hours. Results: We observed a significant elevation of serum KIM-1 levels after the administration of LPS ( P < 0.001). Furthermore, LPS caused a significant elevation of serum creatinine at an early time point ( P = 0.013) as compared with placebo. Conclusion: Even a relatively small inflammatory stimulus is sufficient to cause subclinical structural kidney injury with elevated KIM-1 and serum creatinine in healthy volunteers. This outlines the insufficiency of the current diagnostic approach regarding AKI and the urgency to develop novel diagnostic algorithms including markers of kidney injury. Clinical Trial Registration:www.clinicaltrials.gov . Unique identifier: NCT03392701 (August 1, 2018).
Identifiants
pubmed: 35616594
doi: 10.1097/SHK.0000000000001942
pii: 00024382-202207000-00002
pmc: PMC9415208
doi:
Substances chimiques
Biomarkers
0
Lipopolysaccharides
0
Creatinine
AYI8EX34EU
Banques de données
ClinicalTrials.gov
['NCT03392701']
Types de publication
Clinical Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
14-19Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Shock Society.
Déclaration de conflit d'intérêts
The authors report no conflict of interests.
Références
Bellomo R, Kellum JA, Ronco C, Wald R, Martensson J, Maiden M, Bagshaw SM, Glassford NJ, Lankadeva Y, Vaara ST, et al.: Acute kidney injury in sepsis. Intensive Care Med 43:816–828, 2017.
Bagshaw SM, George C, Bellomo R; ANZICS Database Management Committee: Changes in the incidence and outcome for early acute kidney injury in a cohort of Australian intensive care units. Crit Care 11:R68, 2007.
Zarjou A, Agarwal A: Sepsis and acute kidney injury. J Am Soc Nephrol 22:999–1006, 2011.
Khwaja A: KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 120:c179–c184, 2012.
Gocze I, Jauch D, Gotz M, Kennedy P, Jung B, Zeman F, Gnewuch C, Graf BM, Gnann W, Banas B, et al.: Biomarker-guided intervention to prevent acute kidney injury after major surgery: the prospective randomized BigpAK study. Ann Surg 267:1013–1020, 2018.
Tu Y, Wang H, Sun R, Ni Y, Ma L, Xv F, Hu X, Jiang L, Wu A, Chen X, et al.: Urinary netrin-1 and KIM-1 as early biomarkers for septic acute kidney injury. Ren Fail 36:1559–1563, 2014.
Schrezenmeier EV, Barasch J, Budde K, Westhoff T, Schmidt-Ott KM: Biomarkers in acute kidney injury — pathophysiological basis and clinical performance. Acta Physiol (Oxf) 219:554–572, 2017.
Ichimura T, Asseldonk EJ, Humphreys BD, Gunaratnam L, Duffield JS, Bonventre JV: Kidney injury molecule-1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells. J Clin Invest 118:1657–1668, 2008.
Sabbisetti VS, Waikar SS, Antoine DJ, Smiles A, Wang C, Ravisankar A, Ito K, Sharma S, Ramadesikan S, Lee M, et al.: Blood kidney injury molecule-1 is a biomarker of acute and chronic kidney injury and predicts progression to ESRD in type I diabetes. J Am Soc Nephrol 25:2177–2186, 2014.
Yang L, Brooks CR, Xiao S, Sabbisetti V, Yeung MY, Hsiao LL, Ichimura T, Kuchroo V, Bonventre JV: KIM-1–mediated phagocytosis reduces acute injury to the kidney. J Clin Invest 125:1620–1636, 2015.
Vaidya VS, Ramirez V, Ichimura T, Bobadilla NA, Bonventre JV: Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol 290:F517–F529, 2006.
Shao X, Tian L, Xu W, Zhang Z, Wang C, Qi C, Ni Z, Mou S: Diagnostic value of urinary kidney injury molecule 1 for acute kidney injury: a meta-analysis. PLoS One 9:e84131, 2014.
Arthur JM, Hill EG, Alge JL, Lewis EC, Neely BA, Janech MG, Tumlin JA, Chawla LS, Shaw AD; SAKInet Investigators: Evaluation of 32 urine biomarkers to predict the progression of acute kidney injury after cardiac surgery. Kidney Int 85:431–438, 2014.
Seibert FS, Sitz M, Passfall J, Haesner M, Laschinski P, Buhl M, Bauer F, Babel N, Pagonas N, Westhoff TH: Prognostic value of urinary calprotectin, NGAL and KIM-1 in chronic kidney disease. Kidney Blood Press Res 43:1255–1262, 2018.
Fong YM, Marano MA, Moldawer LL, Wei H, Calvano SE, Kenney JS, Allison AC, Cerami A, Shires GT, Lowry SF: The acute splanchnic and peripheral tissue metabolic response to endotoxin in humans. J Clin Invest 85:1896–1904, 1990.
Michie HR, Manogue KR, Spriggs DR, Revhaug A, O'Dwyer S, Dinarello CA, Cerami A, Wolff SM, Wilmore DW: Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 318:1481–1486, 1988.
Vila G, Riedl M, Resl M, van der Lely AJ, Hofland LJ, Clodi M, Luger A: Systemic administration of oxytocin reduces basal and lipopolysaccharide-induced ghrelin levels in healthy men. J Endocrinol 203:175–179, 2009.
Heinzl MW, Resl M, Klammer C, Egger M, Dieplinger B, Clodi M: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is not induced in artificial human inflammation and is not correlated with inflammatory response. Infect Immun 88:e00842–e00819, 2020.
Vila G, Resl M, Stelzeneder D, Struck J, Maier C, Riedl M, Hulsmann M, Pacher R, Luger A, Clodi M: Plasma NT-proBNP increases in response to LPS administration in healthy men. J Appl Physiol 105(6):1741–1745, 1985.
Clodi M, Vila G, Geyeregger R, Riedl M, Stulnig TM, Struck J, Luger TA, Luger A: Oxytocin alleviates the neuroendocrine and cytokine response to bacterial endotoxin in healthy men. Am J Physiol Endocrinol Metab 295:E686–E691, 2008.
Vila G, Maier C, Riedl M, Nowotny P, Ludvik B, Luger A, Clodi M: Bacterial endotoxin induces biphasic changes in plasma ghrelin in healthy humans. J Clin Endocrinol Metab 92:3930–3934, 2007.
Millischer V, Heinzl M, Faka A, Resl M, Trepci A, Klammer C, Egger M, Dieplinger B, Clodi M, Schwieler L: Intravenous administration of LPS activates the kynurenine pathway in healthy male human subjects: a prospective placebo-controlled cross-over trial. J Neuroinflammation 18:158, 2021.
Andreasen AS, Krabbe KS, Krogh-Madsen R, Taudorf S, Pedersen BK, Moller K: Human endotoxemia as a model of systemic inflammation. Curr Med Chem 15:1697–1705, 2008.
Resl M, Heinzl MW, Klammer C, Egger M, Feldbauer R, Pohlhammer J, Dieplinger B, Clodi M: Storm of cardiovascular markers after LPS administration in human volunteers. J Cardiovasc Transl Res 14:941–947, 2021.
Assarsson E, Lundberg M, Holmquist G, Bjorkesten J, Thorsen SB, Ekman D, Eriksson A, Rennel Dickens E, Ohlsson S, Edfeldt G, et al.: Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS One 9:e95192, 2014.
Shen Q, Bjorkesten J, Galli J, Ekman D, Broberg J, Nordberg N, Tillander A, Kamali-Moghaddam M, Tybring G, Landegren U: Strong impact on plasma protein profiles by precentrifugation delay but not by repeated freeze-thaw cycles, as analyzed using multiplex proximity extension assays. Clin Chem Lab Med 56:582–594, 2018.
Murugan R, Karajala-Subramanyam V, Lee M, Yende S, Kong L, Carter M, Angus DC, Kellum JA; Genetic and Inflammatory Markers of Sepsis (GenIMS) Investigators: Acute kidney injury in non-severe pneumonia is associated with an increased immune response and lower survival. Kidney Int 77:527–535, 2010.
Yin C, Wang N: Kidney injury molecule-1 in kidney disease. Ren Fail 38:1567–1573, 2016.
Khreba NA, Abdelsalam M, Wahab AM, Sanad M, Elhelaly R, Adel M, El-Kannishy G: Kidney injury molecule 1 (KIM-1) as an early predictor for acute kidney injury in post-cardiopulmonary bypass (CPB) in open heart surgery patients. Int J Nephrol 2019:6265307, 2019.
Kellum JA, Prowle JR: Paradigms of acute kidney injury in the intensive care setting. Nat Rev Nephrol 14:217–230, 2018.
Peerapornratana S, Priyanka P, Wang S, Smith A, Singbartl K, Palevsky PM, Chawla LS, Yealy DM, Angus DC, Kellum JA, et al.: Sepsis-associated acute kidney disease. Kidney Int Rep 5:839–850, 2020.